Genmab — Februar 2023
-
For the first time, we report a successful approach to the treatment of refractory anti-NMDAR encephalitis
using the fully human anti-CD20 monoclonal antibody ofatumumab, which serves as an important
reference for the treatment of autoimmune encephalitis. In our cases, satisfactory clinical outcomes were still observed in anti-NMDR encephalitis
while first-line therapy failed. Thus, the case report provides reference for new treatment options of
autoimmune encephalitis -
Our Alem-Ofa dual-targeted immunotherapy study showed that it is an early example of a chemotherapy-free treatment option with several advantages even in the modern treatment era. First the treatment is of a limited and short duration of no longer than 4.5 months. Second, it was able to achieve rapid onset, deep and durable response; most patients needed no additional therapy in the next five years.
-
-
-
Tak gentogen. Hjernebetændelse rammer 250.000 hvert år alene i usa https://www.hopkinsmedicine.org/health/conditions-and-diseases/encephalitis
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind